We are live on ! Find out more
DS

DRW Securities Portfolio holdings

AUM $7.21B
1-Year Est. Return 20.54%
This Fund
S&P 500
This Quarter Est. Return
+5.92%
1 Year Est. Return
+20.54%
3 Year Est. Return
+87.88%
5 Year Est. Return
+88.87%
10 Year Est. Return
+277.95%
AUM
$951M
AUM Growth
+$626M
Cap. Flow
+$622M
Cap. Flow %
65.49%
Top 10 Hldgs %
54.62%
Holding
482
New
417
Increased
15
Reduced
11
Closed
28

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$36.2M
2
VCSH icon
Vanguard Short-Term Corporate Bond ETF
VCSH
+$14.5M
3
AAPL icon
Apple
AAPL
+$12M
4
MCHI icon
iShares MSCI China ETF
MCHI
+$11M
5
IVV icon
iShares Core S&P 500 ETF
IVV
+$9.11M

Top Sells

Rank Stock Value
1
TQQQ icon
ProShares UltraPro QQQ
TQQQ
+$13.2M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$10.7M
3
QLD icon
ProShares Ultra QQQ
QLD
+$9.11M
4
SLV icon
iShares Silver Trust
SLV
+$2.12M
5
TNA icon
Direxion Daily Small Cap Bull 3x ETF
TNA
+$2.04M

Sector Composition

Rank Sector Weight
1 Financials 7.15%
2 Technology 5.55%
3 Healthcare 4.92%
4 Communication Services 3.53%
5 Industrials 2.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OBSV
426
DELISTED
ObsEva SA Ordinary Shares
OBSV
$152K 0.02%
+15,610
New +$159K
SRRA
427
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$149K 0.02%
1,000
+375
+60% +$36K
ARQL
428
DELISTED
Arqule Inc
ARQL
$149K 0.02%
+90,000
New +$117K
CTIC
429
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$138K 0.01%
51,561
+35,000
+211% +$103K
KALV
430
DELISTED
KalVista Pharmaceuticals
KALV
$117K 0.01%
+12,000
New +$125K
TVIX
431
DELISTED
VelocityShares Daily 2x VIX Short Term ETN
TVIX
$113K 0.01%
+204
New +$163K
CBAY
432
DELISTED
Cymabay Therapeutics
CBAY
$110K 0.01%
12,000
-8,000
-40% -$68.4K
ADVM
433
DELISTED
Adverum Biotechnologies
ADVM
$105K 0.01%
+3,000
New +$98.7K
RGLS
434
DELISTED
Regulus Therapeutics
RGLS
$104K 0.01%
+833
New +$105K
ICAD
435
DELISTED
iCAD Inc
ICAD
$94K 0.01%
27,285
+785
+3% +$3.16K
APTO
436
DELISTED
Aptose Biosciences, Inc.
APTO
$90K 0.01%
+89
New +$68.8K
XENE icon
437
Xenon Pharmaceuticals
XENE
$6.32B
$85K 0.01%
+30,000
New +$81.6K
OTIC
438
DELISTED
Otonomy, Inc.
OTIC
$83K 0.01%
+15,000
New +$65.1K
ALDX icon
439
Aldeyra Therapeutics
ALDX
$91.7M
$82K 0.01%
12,000
– –
CFRX
440
DELISTED
ContraFect Corporation
CFRX
$81K 0.01%
+100
New +$82.7K
KDNY
441
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$75K 0.01%
2,000
– –
TARA icon
442
Protara Therapeutics
TARA
$226M
$74K 0.01%
+967
New +$77.5K
STDY
443
DELISTED
SteadyMed Ltd
STDY
$74K 0.01%
+20,000
New +$64.6K
SYRE icon
444
Spyre Therapeutics
SYRE
$8.87B
$70K 0.01%
+515
New +$63K
TNXP icon
445
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
IMDZ
446
DELISTED
Immune Design Corp.
IMDZ
$66K 0.01%
+17,000
New +$92.6K
OMED
447
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$56K 0.01%
+13,740
New +$59.8K
ELDN icon
448
Eledon Pharmaceuticals
ELDN
$276M
$51K 0.01%
+694
New +$52.4K
CHK
449
DELISTED
Chesapeake Energy Corporation
CHK
$50K 0.01%
+64
New +$49.9K
CASC
450
DELISTED
Cascadian Therapeutics, Inc.
CASC
$48K 0.01%
+13,000
New +$53.2K
16 17
18
19 20

Similar funds

CFG
Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.17B AUM 17.27% 1-Year Est. Return
UB
UMB Bank Kansas City, Missouri $7.16B AUM 20.88% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $7.13B AUM 35.47% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

DRW Securities's Q4 2017 Portfolio in Review

As of Q4 2017, DRW Securities held 482 positions worth $951M, up 193% from $324M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

DRW Securities deployed $622M of net new capital in Q4 2017, opening 417 new positions and adding to 15 existing holdings. Its largest new stake was Vanguard Short-Term Corporate Bond ETF: 182,102 shares worth $14.4M.

By sector, the portfolio is most concentrated in Financials at 7.2% of assets, up from 0.1% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, an estimated $1.24M trimmed.

  • DRW Securities's largest Q4 2017 buy was Vanguard Short-Term Corporate Bond ETF: 182,102 shares worth $14.4M.
  • DRW Securities added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $36.2M increase.
  • DRW Securities's biggest Q4 2017 reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, cutting an estimated $1.24M.
  • DRW Securities fully exited ProShares UltraPro QQQ in Q4 2017, selling an estimated $13.2M.
  • DRW Securities's ten largest holdings make up 55% of its $951M portfolio in Q4 2017.
  • DRW Securities opened 417 new positions and closed 28 in Q4 2017.
  • DRW Securities's portfolio value rose 193% quarter-over-quarter to $951M.

Based on DRW Securities's 13F filing for Q4 2017, filed 14 Feb 2018.